Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $206,463.92 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton sold 15,271 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.52, for a total value of $206,463.92. Following the completion of the sale, the chief executive officer now directly owns 895,941 shares in the company, valued at $12,113,122.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mineralys Therapeutics Stock Up 0.8 %

MLYS stock traded up $0.11 during midday trading on Tuesday, reaching $13.70. 65,103 shares of the company’s stock traded hands, compared to its average volume of 176,427. The company has a 50-day simple moving average of $11.89 and a two-hundred day simple moving average of $12.42. The company has a market cap of $680.19 million, a price-to-earnings ratio of -6.21 and a beta of 1.93. Mineralys Therapeutics, Inc. has a 1-year low of $5.85 and a 1-year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same quarter in the prior year, the business earned ($0.31) earnings per share. Equities research analysts forecast that Mineralys Therapeutics, Inc. will post -3.08 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Thursday, August 15th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. lifted its holdings in Mineralys Therapeutics by 17,821.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock worth $35,000 after acquiring an additional 4,099 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Mineralys Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,931 shares of the company’s stock worth $102,000 after acquiring an additional 3,181 shares in the last quarter. SG Americas Securities LLC bought a new position in Mineralys Therapeutics during the third quarter worth about $110,000. Bellevue Group AG bought a new position in Mineralys Therapeutics during the first quarter worth about $119,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Mineralys Therapeutics by 100.0% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $140,000 after purchasing an additional 6,000 shares in the last quarter. 84.46% of the stock is currently owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.